Moderna, Inc. Accounts Receivable, before Allowance for Credit Loss
Moderna, Inc. (MRNA) had Accounts Receivable, before Allowance for Credit Loss of $120.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AccountsReceivableGross · last filed 2026-07-31
- 2026-06-30: Accounts Receivable, before Allowance for Credit Loss $120.00M.
- 2026-03-31: Accounts Receivable, before Allowance for Credit Loss $203.00M.
- 2025-12-31: Accounts Receivable, before Allowance for Credit Loss $368.00M.
- 2025-09-30: Accounts Receivable, before Allowance for Credit Loss $2.02B.
| Period end | Accounts Receivable, before Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $120.00M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $203.00M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $368.00M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $2.02B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $260.00M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $249.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $698.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $2.73B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $492.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $422.00M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.58B 10-K · filed 2025-02-21 |
| 2023-09-30 | $2.36B 10-Q · filed 2023-11-03 |
| 2022-12-31 | $1.39B 10-K · filed 2024-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |